Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don’t take everything you read on here as true.
Just might end up like Cortana and file a lawsuit with that 100 shares
This one?
https://ars.els-cdn.com/content/image/1-s2.0-S2352873718300180-gr1.jpg
I shared it a few weeks back
So just commencing a p3 is a success these days? Come on now.
Ducks are lining up, failures are moving out of the way, and Anavex will have their chance to show what they can do.
Until then, I’m sure there will be many attempts to take my shares.
Nice summary of board topics the last 7 Days.
Although we all shouldn’t get too excited as games are and will still be played.
Retail thinks otherwise.
“To promote the most promising opportunities and address the
corresponding intricacy of these new endeavors, the FDA has introduced
many fundamental advances in how it evaluates drugs for safety and
effectiveness, as well as the manner in which clinical trials are
guided. These include adaptive approaches to clinical development such
as the introduction of seamless trial designs or master protocols or
tissue agnostic product approvals. Each allow us to better marry the
scientific prospect more closely to the approaches that can best
unlock these opportunities.
https://www.news-journal.com/ap/national/statement-from-fda-commissioner-scott-gottlieb-m-d-on-proposed/article_3c3cd278-f6cb-5ad2-b045-9b44a2f32b26.html
I’m from Hawaii. And here you can go from a dormant volcano with snow to a full blown erupting volcano within a span of 3 hours. So we may be the dormant volcano right now, but we can erupt at any time
Ah, the so called “experts” that bleed plaque as the problem. THAT is why there were soooooo many failures.
Hence the waterfall on the website?
Sweeping clinical trials in which thousands of patients are studied for years at a stretch have long been the Holy Grail of medical research—especially when funded by the federal government.
But in the era of personalized medicine, where care can be tailored to a person’s genetic make-up and doctors analyze a patient’s DNA to figure out treatments, big trials are falling out of favor.
Hmm...
https://www.wsj.com/articles/are-big-clinical-trials-relevant-researchers-disagree-1527599699
Attacking website design now? Lol
Yes it’s created on Wordpress just like many small bios.
I even helped them close root access to the site.
I’d much rather have the compound that could possibly work and a plain website than a shinny perty website and no compound ex. AX*N
Yes they are on the right under small molecule disease modifying, tau related and mild-moderate.
Pie chart of ongoing trials for Alz
https://ars.els-cdn.com/content/image/1-s2.0-S2352873718300180-gr1.jpg
With so much failure, and trials going on, one can see why it’s easy to bash ANY of those trials and be over 95% correct.
Bottom line:
I wait for trials to start
I wait for trial results
I re-evaluate from there.
Until then, speculation galore.
May be helping? Lol. Until we get an update of the patients in the Aus trial, we have improved checkpoints SO FAR.
Then again, why wouldn’t they want to take the soc, since it’s proven to slow decline a month or two?
Yup, why slow it a month or two when the side effects aren’t worth it.
4 people I knew died the last 5 years from cancer. Talk about snake oil BP is pushing to the sick.
Yup, it’s why I switched from those chemically made sugars to the regular ol c&h sugar for my coffee.
Sure they can advertise it as a better alternative only to find out years later that it’s linked to the cause of this disease or that problem.
IMO, with the extension into 2020, looks like the data gathered from the p2 will be used to help project what is the expected outcome for the p2/3. Glad they have the compassion to let the trial participants continue their medicine, and hopefully for the better.
One could say that the predators, BP, want to know how Anavex is doing. So they try and force the company to release updates or PRs by any means necessary. The silence is killing them as well because Anavex isn’t “sharing with concerned investors”.
Will they succeed, no one knows. What Anavex IS doing is giving their candidate a shot at goal multiple times. Surviving greed and the likes in the process.
I’d think time is running out to cover them short sells
Lol, years.
Sure, because the countries around the world can afford to wait for an effective drug.
Thousands of participants are obviously wrong now as that article was from April 2016 and it’s been said many times that it’ll be about 350.
That is, WHEN, it finally starts.
If p2/3 comes out positive, by the time peers review the results/ data, the stock will be out of reach to buy for most folks.
I believe he changed strategy due to an unknown reason to us. Maybe someone were aggressive with trying to lowball the co.
Maybe to us we see transparency to manipulators its an advantage. Knowing when to be aggressive or not.
Were you were here before the big drop from $14?
Compare how it was then, to how it is now.
So rushing into a trial, clueless at what to target using previously known years long requirements is what is suggested?
That’s how trials fail, even if you ARE BP and looking for someone to bribe.
The link between your gut health and autoimmune diseases
https://www.yahoo.com/lifestyle/link-gut-health-autoimmune-disorders-120024072.html
Which is probably why BP is pulling out of AZ trials. With transparency comes hopefully less of those shady type deals where I scratch your back, I get offered something in return.
“AD its a tough nut to crack, and a single compound therapy is unlikely”
And aricept, the prescription of choice that benefit the patients very little, has been the therapy how long?
Most I amazingly have to agree, but if a-273 proves itself again in p2/3, it WILL be the newly prescribed medicine for patients until something better comes along.
Well, it is this part that I especially posted the article.
“One such strategy is the use of natural history models to reduce the need for placebo arms in studies of therapies targeting very rare conditions. The FDA defines the natural history of a disease as the course an illness takes from its onset, through the presymptomatic and clinical stages, to a final outcome in the absence of a treatment.”
For all the Debbie’s that say placebo is a must, it’s the old way of thinking.
One important change is that FDA says it’s open to considering a novel drug for early stages that can affect cognition, or measures of a person’s thinking or memory. FDA previously said a drug had to deliver on two endpoints: cognition and function, and the latter involves an ability to perform tasks.
https://www.wsj.com/articles/cures-welcome-at-fda-1520803007
And who laughed at Netflix when they came knocking on the door? Yup, Blockbuster. Didn’t want anything to do with them.
Yes fireman.
By they remaining silent, we are to assume that it means Anavex is on the wrong path. That they, BP, the all knowing companies with endless funds are always right.
No, they don’t buy out smaller companies that take all the risk leaving them with a small portion of all the rewards.
They don’t hire desperate people to post on public boards to down right slander a company making the uninformed “think” its a bad investment, when nothing except positives have been shared since 2014.
Yes it has taken a while, but in any other scenario, we would have been either bought out on the cheap, or down in the RS world never having the chance to take a-273 to the pivotal trial.
I’ll be voting FOR this April.
Which is why retail miss out when pps REALLY appreciates.
Happens time and time again.
Surely a CEO owning 2.2 percent of the company means nothing also?
Between Park West and the Dr. , they own a little over 8% of the 44M stock available.
Neither of them selling as the pps went from $5 to mid $2.
Yet liar is all that can be said of the CEO? Have to be more creative than that as preclinicals keep piling up showing the possibilities of a-273.
While the ones with a lot of shares would keep the CEO and board exactly how it is.
Sure one can say that it’ll happen again until it doesn’t. Just as how the pps must go down again because it always does.
He very well could be diluting as we are above $3 , which is the LPC agreement unless I read an earlier post wrong.
It was a question not a smart a$$ remark.
Like it or not about that BIIB testing, you know nothing more than I do about it. Yet, I don’t cling onto it like it’s the ONLY thing that a-273 has going for it.
Something may come of it, something may not.
BP seems to be tucking tail and running when it comes to Alz trials. Maybe they finally figured something out we all have been saying for a long time.
20 years and Billions of dollars and nothing more than a extra month or 2 of a life forgotten.
You think if BP had a-273 in their hands they would have known what to target? Or just send to trial and cross their fingers?